α-葡萄糖苷酶抑制剂维力波糖改善糖尿病大鼠糖脂代谢紊乱及肾脏病变

Valibose,an alpha-glucosidase inhibitor,ameliorates the metabolic disorder of glucose and lipids and the nephropathy in streptozotocin-induced diabetic rats

考察新型α-葡萄糖苷酶抑制剂——维力波糖对糖尿病大鼠的糖脂代谢紊乱及糖尿病肾病的改善作用。链脲霉素糖尿病大鼠饲以高糖饲料喂养后,餐后血糖、空腹血糖、糖化血清蛋白以及尿糖含量显著高于正常大鼠,并存在一定程度的肾脏病变。长期给予维力波糖后能够显著降低糖尿病大鼠的空腹血糖、餐后血糖、糖化血清蛋白、血清甘油三酯、总胆固醇及尿糖水平,改善多食多饮等症状。维力波糖还能够显著降低血清N-乙酰-β-D-氨基葡萄糖苷酶活性和尿素氮水平,降低该模型的肾脏指数。结果表明,维力波糖通过有效控制餐后高血糖改善了糖尿病大鼠的糖脂代谢紊乱,同时也一定程度改善了糖尿病大鼠的肾脏病变,有益于缓解糖尿病微血管并发症的发生和发展。

This study is to evaluate the anti-diabetic effects of the alpha-glucosidase inhibitor valibose in a streptozotocin （STZ）-induced type 1 diabetes rat model. Diabetes was induced by a single dose of STZ （58 mg·kg？1, ip） in SD rats, rats with elevated fasting blood glucose levels （250？450 mg·dL？1） were selected and divided into five groups （n = 10 in each）. Another ten normal SD rats were chosen as normal group. Valibose mixed with the high sucrose diets （0.4, 1.0 and 2.5 mg·100 g？1 diets） or acarbose （30 mg·100 g？1 diets） was administrated in the diabetic rats for about 5 weeks. In all groups, fasting and postprandial plasma glucose, plasma lipids, glycosylated serum protein, N-acetyl-beta-D-glucosaminidase （NAG）, creatinine （Cre）, blood urea nitrogen （BUN） and urine sugar levels were determined during the treatment. At the end of the experiment, the morphological alterations in kidney were evaluated by hematoxylin-eosin （HE） staining. After 3-weeks administration, valibose significantly decreased postprandial and fasting blood glucose, urine glucose, and reduced the levels of serum fructosamine. Valibose also decreased plasma triglyceride and cholesterol levels after 4 weeks treatment. These results indicated that valibose ameliorated metabolic disturbance of glucose and lipids in STZ-induced diabetic rats. In addition, valibose markedly reduced level of serum NAG and BUN, and decreased the weight index of kidney. HE staining showed reduced kidney pathological changes after valibose treatment. The findings of the present study indicate that valibose may be a novel α-glucosidase inhibitor for the prevention from hyperglycemia in STZ-induced type 1 diabetes rats. And valibose might have a potential role for protecting against diabetic nephropathy during hyperglycemia.